Skip to main content
. 2020 Apr 30;2(5):294–299. doi: 10.1002/acr2.11139

Figure 1.

Figure 1

Uveitis in pooled secukinumab ankylosing spondylitis (AS) clinical trials. Rates reported are n (%) for the entire treatment period (N = 794) for preferred terms by using the Medical Dictionary for Regulatory Activities. aIncludes two cases of treatment discontinuation and one case of treatment interruption.